When OREX can prove that Contrave is GOOD for the heart,
they'll have a new indication on the market.
"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alcatel Lucent ..."
Where's the rest of the team?
There is a possible CV benefit and hopefully the FDA and OREX can work this in as a
secondary end point in the next "light study", if there is one. However long before the
results of that study, we will have results of a Phase 2 CV benefit clinical trial.
Something the prescribing physicians will see and the sales force will not have to promote.
In an indirect (patent publication) way, yes. They may prove it in a Phase 2 clinical study.
They're just building their pipeline like a good little bio.
The FDA didn't say anything. A loose cannon employee gave off-the-cuff
remarks to a Forbes blogger.
Why are you posting here, if ARNA is in a different market?
Go pester your competition. ARNA is losing the weight loss
market to OREX.
ARNA better do something before being left in the dust.
OREX needs better support from their competitors in
promoting the weight loss industry. Giant market, little
penetration. Like Mark Booth said yesterday, OREX
is not interested the small ARNA and VVUS portion but
in the average fat guy out there.
All bios have "legal issues". Strong patents protect their rights (except in India).
These ambulance chasers will have their case thrown out once they are consolidated.
Expect "deals and additional sales" to happen way before this.
You listened but didn't hear.
OREX is going after the big market, not the peanuts that VVUS and ARNA have.
They priced their product to not be much more than those that are insurance covered.
THE WHOLE MARKET! As far as they are concerned, the more the competition
advertises the better. Doctors have to realize the cost benefits of weight loss
for heart and diabetes conditions.
Let's go ARNA and VVUS, get your butts in gear!
Who has no revenue?...most developing small biotechs. Who has no partners?...
most small biotechs with no FDA approved products to sell.
Whom are you talking about?
I really don't expect an answer. Please advise?
$200,000,000 cash as of 12/31/2014.
A cash premium about to be received from one or two of MANY competing
potential EU/ROW partners.
Not growing as fast as Contrave. Tell the whole story. Listen to today's OREX
webcast and realize that OREX is after the giant market, not ARNA's and VVUS's
small market share. This large market has not yet been served.
Where is "the FDA response"? The only thing I can find is from their
unofficial loose cannon making off the cuff remarks to a Forbes blogger.
How old is my ID (only one I have)? How old is your's?
Read the lines (which you are incapable of writing).
How much education do you have? Your boiler room
employer has to increase his basher budget.
You are confused. The second "light study" is planned to further evaluate
cardiovascular (CV) outcomes. This may go on for years unless it is found
that those in the study taking the placebo are at risk or those on the real pill
are at risk. If either, the FDA would cancel the study. If Contrave/Mysimba
is dangerous they would pull the drug off the market at that time.
Before the second "light study" is concluded, OREX would have completed
their Phase 2,3 NDA process, if the drug is shown to have CV benefit in this
process. SEPARATE STUDY! CV benefit and weight loss are two
applications. Like Arena, there may be more. New patents coming?
Put your propeller hat.
What's a "mislabeling patent"? OREX has said: "A second study, designed to address post-approval requirements in both Europe and the United States, is planned in order to further evaluate cardiovascular outcomes". The 25% data suggested CV benefit, the 50% data MAY confirm it. A new Phase 2 study
will test their new patent claim of CV benefit, followed up by a Phase 3 study, leading to a NDA. You
know the process don't you? Developing a pipeline.